Cytokine storm in COVID-19: the current evidence and treatment strategies
Y Tang, J Liu, D Zhang, Z Xu, J Ji, C Wen - Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …
[HTML][HTML] Immunopathology of Hyperinflammation in COVID-19
JN Gustine, D Jones - The American journal of pathology, 2021 - Elsevier
The rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome–coronavirus 2 (SARS-CoV-2), has resulted in an unprecedented …
respiratory syndrome–coronavirus 2 (SARS-CoV-2), has resulted in an unprecedented …
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
G Guaraldi, M Meschiari, A Cozzi-Lepri… - The Lancet …, 2020 - thelancet.com
Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …
Ferritin in the coronavirus disease 2019 (COVID‐19): a systematic review and meta‐analysis
L Cheng, H Li, L Li, C Liu, S Yan… - Journal of clinical …, 2020 - Wiley Online Library
Objective The coronavirus disease 2019 (COVID‐19) has rapidly developed into a
pandemic. Increased levels of ferritin due to cytokine storm and secondary hemophagocytic …
pandemic. Increased levels of ferritin due to cytokine storm and secondary hemophagocytic …
Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial
C Salvarani, G Dolci, M Massari, DF Merlo… - JAMA internal …, 2021 - jamanetwork.com
Importance The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of
people worldwide. Tocilizumab has shown promising results in retrospective studies in …
people worldwide. Tocilizumab has shown promising results in retrospective studies in …
The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?
The outbreak of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) infection, has emerged in China in December 2019 …
Syndrome Coronavirus 2 (SARS-CoV-2) infection, has emerged in China in December 2019 …
The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection
In severe SARS-CoV-2 infections, emerging data including recent histopathological studies
have emphasized the crucial role of endothelial cells (ECs) in vascular dysfunction …
have emphasized the crucial role of endothelial cells (ECs) in vascular dysfunction …
Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19
Importance Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …
Tocilizumab for treatment of mechanically ventilated patients with COVID-19
Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …
decompensation and respiratory failure with elevated inflammatory markers, consistent with …
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …